Bromocriptine and Tolcapone interaction
Bromocriptine and Tolcapone: the Tolcapone prescribing label flags this combination with the strongest language, such as a contraindication, a boxed warning, or an instruction to avoid it.
Do not combine without a prescriber's guidance. The label language below is the strongest FDA uses.
What the FDA labels say
From the Tolcapone label · effective 2020-10-01
Tolcapone tablets is also contraindicated in patients with a history of nontraumatic rhabdomyolysis or hyperpyrexia and confusion possibly related to medication (see PRECAUTIONS: Events Reported With Dopaminergic Therapy ).
PRECAUTIONS: Hypotension/Syncope: Dopaminergic therapy in Parkinson's disease patients has been associated with orthostatic hypotension.
Baseline treatment with dopamine agonists or selegiline did not appear to increase the likelihood of experiencing orthostatic hypotension when treated with Tolcapone tablets.
Dyskinesia: Tolcapone tablets may potentiate the dopaminergic side effects of levodopa and may cause and/or exacerbate preexisting dyskinesia.
These reports are associated with patients taking Tolcapone tablets in conjunction with carbidopa/levodopa, as well as other medications that increase central dopaminergic tone and that are used to treat patients with Parkinson’s disease.
Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.
Open in the checkerNot medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.